Boehringer announces collaboration with PetMedix
PetMedix's Ky9 platform can rapidly and efficiently generate fully canine therapeutic antibodies.
Boehringer Ingelheim has announced a multi-year partnership with PetMedix - a Cambridge-based biopharmaceutical firm - to develop novel and transformative companion animal antibody therapeutics.
The collaboration will see PetMedix undertake discovery activities against a number of key targets and Boehringer Ingelheim will work to develop and bring these therapies to market. The terms of the partnership have not been disclosed.
PetMedix’s breakthrough approach to therapeutic antibodies has resulted in a number of successful, novel therapies for humans. It is also the only company in the world that has been able to bring this approach to veterinary medicine.
Through its its Ky9™ platform, PetMedix can rapidly and efficiently generate fully canine therapeutic antibodies. This approach saves time and money in drug development, and reduces the risk of certain key adverse events relative to other antibody technologies.
Dr Tom Weaver, CEO of PetMedix, said: “We are excited to be working with Boehringer Ingelheim on this project as we feel we bring complementary experience and expertise to this partnership. PetMedix has developed the leading pet antibody discovery engine, and it will be through Boehringer Ingelheim’s global scale and industry leadership that these novel therapies will best be able to succeed and ultimately benefit the animals.”
James Allan, global head of transaction, business development & licensing, Boehringer Ingelheim Animal Health, added: “Boehringer Ingelheim is pleased to be working with PetMedix on this cutting edge technology as a means to bring innovative new therapies to improve the health of animals globally. PetMedix has a unique expertise and its focus on innovation aligns well with our own”.
FIVP has shared a survey, inviting those working in independent practice to share their views on the CMA's proposed remedies.
